VOR BIOPHARMA INC
NASDAQ: VOR (Vor Biopharma Inc.)
Kemas kini terakhir: 18 jam lalu22.30
-0.04 (-0.18%)
| Penutupan Terdahulu | 22.34 |
| Jumlah Dagangan | 800,244 |
| Harga / Buku (P/B) | 0.660 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.51 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 46.59% |
| Nisbah Semasa (MRQ) | 3.88 |
| Aliran Tunai Operasi (OCF TTM) | -100.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -61.85 M |
| Pulangan Atas Aset (ROA TTM) | -55.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -125.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vor Biopharma Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.67 |
|
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 43.00% |
| % Dimiliki oleh Institusi | 46.77% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |